{
  "schemaVersion": 1,
  "id": "research-308",
  "slug": "308-why-the-bremelanotide-extension-study-cannot-replace-a-placebo-comparison",
  "title": "Why the Bremelanotide Extension Study Cannot Replace a Placebo Comparison",
  "catalogLabel": "PT-141",
  "productCollection": "https://heritagebiolabs.com/research-library/products/pt-141",
  "productHandles": [
    "pt-141-449"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/pt-141-449"
  ],
  "readingFocus": "Interpreting evidence",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 271,
  "sourceYears": [
    2019,
    2026
  ],
  "paragraphs": [
    "A peptide is a short chain of amino acids joined by peptide bonds. When a peptide is developed as a medicine, researchers may follow participants after a controlled trial to look for patterns that need longer observation. PT-141, or bremelanotide, had a 52-week extension after the controlled phase of the RECONNECT studies. The older extension is the direct source for this comparison of study designs. Its results should be read alongside the current US labeling. [1, 2]",
    "James Simon and colleagues reported that 684 of 856 eligible participants who completed the original phase chose to enter the extension. In the extension, everyone received active treatment and knew it. A total of 272 completed the extension. The researchers continued to collect adverse event reports and questionnaire scores. They reported no new safety signal and continued improvements in some measures among participants with observations. Nausea, flushing and headache were commonly reported. [1]",
    "The extension helps describe what was observed with longer exposure in a group willing and eligible to continue. It has two important limits. There was no concurrent placebo comparison during the extension. In addition, a large number of participants did not finish it. The people who stayed may have differed in their experience of effects or tolerability from those who left. An average among people who remained does not answer what would happen to all of the original participants. [1]",
    "An open-label extension can therefore complement a controlled trial. It can reveal observations worth tracking and show how follow-up participation changes. It cannot establish that every sustained change was caused by the drug or rule out uncommon adverse effects. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Simon JA et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstetrics & Gynecology (2019-11).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/31599847/"
    },
    {
      "number": 2,
      "citation": "US Food and Drug Administration. Vyleesi (bremelanotide) prescribing information. Drugs@FDA (revised 2026-10).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005lbl.pdf"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/308-why-the-bremelanotide-extension-study-cannot-replace-a-placebo-comparison",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/308-why-the-bremelanotide-extension-study-cannot-replace-a-placebo-comparison.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/308-why-the-bremelanotide-extension-study-cannot-replace-a-placebo-comparison.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 062 - PT-141 and RETA GLP-3.docx",
    "sourceArticleNumber": 308,
    "contentSha256": "266b41677c6e4accd1896697d664dadf327c6d1e49b241049bea56371eb12713",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
